Crestor Dosing for High-Risk ASCVD Patients

Introduction to High-Intensity Statin Therapy

• The American College of Cardiology recommends initiating rosuvastatin 20 mg daily as high-intensity statin therapy to achieve ≥50% LDL-C reduction and maximize cardiovascular risk reduction in patients with an 18% 10-year ASCVD risk 1, 2
• High-intensity statin therapy reduces major cardiovascular events more effectively than moderate-intensity therapy in high-risk patients, with a significant reduction in ASCVD events 3, 4

Rationale for LDL-C Reduction

• The American College of Cardiology suggests that greater LDL-C reduction translates directly to greater cardiovascular benefit, with each 38.7 mg/dL reduction in LDL-C producing approximately 20-28% relative risk reduction for cardiovascular events 4, 5
• The JUPITER trial demonstrated that rosuvastatin 20 mg daily achieved a median 50% LDL-C reduction and significantly reduced ASCVD events after only 1.9 years in primary prevention patients 1, 2

Dosing Algorithm by Risk Level

• For patients with a 10-year ASCVD risk ≥20%, the American College of Cardiology recommends starting rosuvastatin 20 mg daily to achieve maximal risk reduction 1, 2
• For patients with a 10-year ASCVD risk 7.5-19.9%, rosuvastatin 20 mg daily is reasonable when maximal ASCVD risk reduction is desired after risk discussion 1, 2

Follow-Up and Titration

• If LDL-C remains ≥70 mg/dL on maximally tolerated statin therapy, the American College of Cardiology suggests adding ezetimibe 10 mg daily, which provides additional 15-25% LDL-C reduction 3, 6
• If LDL-C still ≥70 mg/dL after statin plus ezetimibe, consider adding a PCSK9 inhibitor in very high-risk patients 3, 6